The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCTX | -93.99% | N/A | N/A | -100% |
| S&P | +12.94% | +86.25% | +13.25% | +243% |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
No news articles found for BriaCell Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 63.2% |
| Market Cap | $14.05M | 2.1% |
| Market Cap / Employee | $0.83M | 0.0% |
| Employees | 17 | -5.6% |
| Net Income | -$8.16M | -553.8% |
| EBITDA | -$8.53M | -49.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $10.49M | 1117.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -191.21% | -162.2% |
| Return On Invested Capital | 108.03% | -95.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.87M | -102.4% |
| Operating Free Cash Flow | -$8.87M | -125.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.28 | 4.11 | 2.36 | 0.79 | -113.60% |
| Price to Tangible Book Value | -863.74 | 31.48 | 38.53 | 4.00 | -101.37% |
| Enterprise Value to EBITDA | -3.13 | -1.13 | -0.57 | 0.55 | -125.30% |
| Return on Equity | -490.7% | -602.6% | -339.5% | - | |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
